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HYPOTHESIS Open Access
Does activation of the protective Renin-
Angiotensin System have therapeutic
potential in COVID-19?
Pawel Namsolleck1 and Gert N. Moll1,2*
Abstract
Infection of lung cells by the corona virus results in a loss of the balance between, on the one hand, angiotensin II-
mediated stimulation of the angiotensin II type 1 receptor and, on the other hand, stimulation of the angiotensin II
type 2 receptor and/or the Mas receptor. The unbalanced enhanced stimulation of the angiotensin II type 1
receptor causes inflammation, edema and contributes to the pathogenesis of severe acute respiratory distress
syndrome. Here we hypothesize that stable, receptor-specific agonists of the angiotensin II type 2 receptor and of
the Mas receptor are molecular medicines to treat COVID-19 patients. These agonists have therapeutic potential in
the acute disease but in addition may reduce COVID-19-associated long-term pulmonary dysfunction and overall
end-organ damage of this disease.
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Recent publications highlight ACE2 as a cell-entry receptor
for SARS-CoV and SARS-CoV-2. Less attention is given to
other, in particular protective, components of the Renin
Angiotensin System (RAS) (Unger et al. 2015). RAS has a
double nature, like the two-faced ancient Roman god Janus,
which simultaneously looks in opposite directions. The Det-
rimental Arm of RAS is formed by the ACE-Angiotensin II
(Ang II)-angiotensin II type 1 receptor (AT1R) axis. Limiting
the detrimental effects of AT1R by AT1R blockers (ARBs) or
by inhibiting RAS via ACE inhibitors (ACEi) is generally
well-established. However, the use of ARBs and ACEi in
coronavirus disease-2019 (COVID-19) has been subject of
debate. On the other hand, as part of the Protective Arm of
RAS, Ang II also stimulates the angiotensin II type 2
receptor (AT2R) and this octapeptide can be further cleaved
by the carboxypeptidase ACE2 to yield angiotensin-(1–7)
(Ang-(1–7)), an agonist of the Mas receptor (MasR). The
protective effects of AT2R and MasR agonists are usually
opposite to the detrimental effects of AT1R, but their
clinical use, in cases of unbalance between the two Arms of
RAS, is insufficiently explored. Endogenous ligands of the
RAS receptors are rapidly degraded and lack receptor
specificity. Here we consider therapeutic perspectives of
stable and specific AT2R and MasR agonists in COVID-19.
The balance between the Detrimental and Protective
Arm of RAS is in several aspects seriously disturbed in
COVID-19, thus causing a potentially lethal disease (Fig. 1).
After the SARS-CoV cell-entry following ACE2-interaction,
subsequent down-regulation of cell surface ACE2 is
observed (Kuba et al. 2005). Since SARS-CoV-2 also targets
ACE2, likewise downregulation of ACE2 is expected.
Reduced membrane expression of ACE2 enhances the
inflammatory response to the virus. COVID-19 infection
furthermore causes an increase in the decapeptide Ang I
and the octapeptide Ang II, whereas Ang-(1–7) levels
decrease. Thereby detrimental Ang II-mediated stimulation
of AT1R is enhanced whereas protective Ang-(1–7)-medi-
ated stimulation of MasR is decreased. AT1R stimulation
reduces alveolar cell survival. It also causes inflammation
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and an increase in vascular permeability (Huertas et al.
2020). As a result, edema is accumulating in the alveoli
which hampers gas-exchange leading to lower oxygen
levels. Taken together this adds to the severity of the acute
respiratory distress.
Reduction of the unbalance in the RAS by inhibition of
the Detrimental Arm might be reached by either an ARB
or an ACEi. The combined use of ARBs and ACEi is
prohibited, but their single use is applied. ARBs block the
AT1R and thus Ang II can activate the unopposed protect-
ive receptor AT2R and further, after ACE2-mediated
conversion of Ang II into Ang-(1–7), also the MasR. Unfor-
tunately, ARBs exert only limited therapeutic effect in tissue
injury (Unger et al. 2015). Moreover, ARBs may reduce
blood pressure, which in case of critically ill patients may
lead to unwanted hypotension. ACEi block the ACE-
mediated cleavage of Ang I and thereby block the forma-
tion of Ang II. Pros and cons of the use of ARBs and ACEi
in COVID-19 have been discussed (D'Ardes et al. 2020).
Continuation of the use of an ARB or an ACEi in COVID-
19 has been recommended (Vaduganathan et al. 2020;
Ingraham et al. 2020; Park et al. 2020; Sanchis Gomar et al.
2020) and has been suggested to be beneficial in cardiovas-
cular disease (Wang et al. 2020). Fear for induction of
upregulation of the CoV-2-receptor ACE2 leading to
enhanced infection (Sommerstein and Gråni 2020) has not
been supported by clinical data (Gupta and Misra 2020; Kai
and Kai 2020). In fact a clinical investigation demonstrated
that no ARB or ACEi-induced upregulation of ACE2 takes
place (Sriram and Insel 2020). On the other hand, benefits
with respect to reducing COVID-19 itself have not (yet)
been demonstrated in the clinic either (Gupta and Misra
2020; Kai and Kai 2020; Rico-Mesa et al. 2020). Instead of
blocking AT1R or inhibiting ACE, here we focus on the
potential benefits in COVID-19 of stimulating the AT2R or
MasR.
Restoration of the balance in the RAS after corona virus
infection might be pursued by direct and specific stimulation
of the Protective Arm via AT2R or via the ACE2 - Ang-(1–
7) - MasR axis. In a subchronic lung injury model a cyclized
AT2R-specific peptide agonist, with a half-life of > 2 h in
man, reduced inflammation and hypertrophy (Wagenaar
et al. 2013). In an animal model of monocrotaline-induced
pulmonary hypertension, a small molecule AT2R agonist
C21 reversed pulmonary fibrosis and prevented right
ventricular fibrosis. Furthermore C21 improved right heart
function, decreased pulmonary vessel wall thickness, and
reduced pro-inflammatory cytokines (Bruce et al. 2015). In a
bleomycin-induced lung injury model prolonged administra-
tion of the AT2R agonist C21 prevented and attenuated
pulmonary fibrosis, collagen deposition and lung remodel-
ing. In addition C21 reduced inflammation, improved lung
pressure and reduced muscularization of the pulmonary
vessels (Rathinasabapathy et al. 2018). Currently the safety
and efficacy of this agonist is tested in a Phase 2 trial with
patients with COVID-19 infection (ClinicalTrials.gov Identi-
fier: NCT04452435).
Recombinant human ACE2, which is not membrane
bound, still binds to the corona virus and thereby limits the
cell entry (Fig. 1). Furthermore recombinant ACE2 converts
Fig. 1 Potential treatments of SARS-CoV-2 infection within the Renin Angiotensin System containing a summary of an animal model of acute
respiratory distress syndrome (Wösten-van Asperen et al. 2011)
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Ang II into Ang-(1–7). In patients with pulmonary arterial
hypertension a single dose of recombinant human ACE2
resulted in a decreased level of pro-inflammatory cytokines
and markers of oxidative stress accompanied by decreased
pulmonary vascular resistance and increased cardiac output
(Hemnes et al. 2018). To elucidate the molecular mecha-
nisms leading to the observed effects, RNAseq on pulmon-
ary arteries treated ex vivo with MasR agonist AVE0991
was performed. Significant changes in pressure regulation,
inflammatory responses and cell migration pathways were
observed indicating therapeutic effects of MasR activation
(Hemnes et al. 2018). Stimulation of the MasR reduces
in vitro Ang II- or bleomycin-induced apoptosis of alveolar
epithelial cells (Uhal et al. 2011).
A recent review speculates on potential benefits of MasR
stimulation in COVID-19 based on data obtained from
animal models of asthma, lung fibrosis, ARDS, and pul-
monary emphysema. The anti-inflammation effects, such as
decreased cytokine and chemokine synthesis, migration of
inflammatory cells to the lung and the resulting functional
improvement of the lungs would be key benefits of MasR
stimulation (Fig. 2). In addition, prolonged treatment might
Fig. 2 Anti-inflammatory and anti-fibrotic pathways mediated by activated AT2R and/or MasR. The AT2R and MasR are expressed in the cell as
monomers, homodimers and AT2R-MasR heterodimers (Leonhardt et al. 2017) and their downstream pathways are largely similar, making it often
impossible to distinguish between them. During infection the AT1R becomes activated initiating inflammatory processes via NFκB and MAPK. Prolonged
activation of AT1R may initiate pro-fibrotic processes with TGFβ as a key molecule. Agonist-mediated stimulation of AT2R or MasR inhibits activation of
NFκB and MAPK resulting in anti-inflammation. For the anti-fibrotic action the inhibition of receptor tyrosine kinase activity by dephosphorylation on the
one hand, and activation of cGMP on the other hand, plays a crucial role. In addition, heterodimerization between AT1R and AT2R or MasR inhibits
detrimental effects mediated by AT1R. Blue lines: pro-fibrotic pathways; red lines: pro-inflammatory pathways; green lines: anti-inflammatory or anti-
fibrotic pathways. AT2R / MasR: angiotensin II type 2 receptor or Mas receptor or AT2R-MasR heterodimers; TGFBR2: transforming growth factor beta
receptor II; AT1R: angiotensin II type 1 receptor; RTKs: receptor tyrosine kinases; Akt: protein kinase B; PTP: protein tyrosine phosphatase; PSP: protein
serine/threonine phosphatase; eNOS: nitric oxide synthase 3; NO: nitric oxide; cGMP: cyclic guanosine monophosphate; MMP9: matrix metallopeptidase 9;
TGFβ: transforming growth factor beta; PDGF: platelet-derived growth factor; FGF: fibroblast growth factor; CTGF: connective tissue growth factor; VEGF:
vascular endothelial growth factor; ECM: extracellular matrix; ERK: extracellular signal-regulated kinases; MAPK: mitogen-activated protein kinase; NOX:
NADPH oxidase; ROS: reactive oxygen species; NFκB: nuclear factor kappa B; Gαi: G protein alpha i subunit; ATIP: AT2R-interacting proteins/microtubule-
associated scaffold proteins; PP2A: protein phosphatase 2A; SHP-1: Src homology region 2 domain-containing phosphatase-1; MKP-1: MAPK Phosphatase
1. The pathways are based on: Unger et al. 2015; Sumners et al. 2019; Zhang et al. 2014; Leonhardt et al. 2017; Chappell and Al Zayadneh 2017
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result in anti-fibrotic effects in lung tissue (Magalhaes et al.
2020).
The potential of the ACE2 - Ang-(1–7) - MasR axis
has furthermore been recognized as witnessed by regis-
tered clinical trials of Ang-(1–7) in COVID-19 (Clinical-
Trials.gov, Identifiers: NCT04332666; NCT04375124;
NCT04401423). However, endogenous Ang-(1–7) lacks
receptor specificity. Ang-(1–7) stimulates in vivo the
MasR but in vitro studies reported biased agonism at the
AT1R (Galandrin et al. 2016). In addition, Ang-(1–7) is
very rapidly degraded resulting in a half-life of less than
a minute in man. In contrast, specific and stable cyclic
Ang-(1–7) exerts multiple therapeutic effects in lung
tissue of animal models of acute and chronic lung injury
(Wagenaar et al. 2013; Wösten-van Asperen et al. 2011).
In an animal model of ARDS, cyclic Ang-(1–7) re-
duced lung injury and inflammation while improving
blood oxygenation (Fig. 1). Cyclic Ang-(1–7), which is
fully ACE-resistant, did not change the blood pressure
(Wösten-van Asperen et al. 2011). In addition to the
acute and sub-chronic effects in COVID-19, stable AT2R
agonists (Bruce et al. 2015) may reduce COVID-19-
associated long term pulmonary dysfunction.
Besides the lungs, COVID-19 also affects heart, kidney,
liver, gastrointestinal and the central nervous systems
(Gan et al. 2020). In view of the demonstrated general
therapeutic potential of the Protective Arm of RAS in
these organs and systems (Unger et al. 2015), treatment
of severe ARDS in COVID-19 with AT2R and MasR
agonists may concomitantly confer beneficial effects that
reduce the overall end-organ damage of this disease.
In conclusion, available data indicate the perspective
of an effective strategy for treatment of ARDS and
COVID-19 by direct and selective stimulation of the
Protective Arm of RAS by AT2R- or MasR-specific, pep-
tidase-resistant agonists. The data converge to further in-
vestigations in viral pneumonia-mediated ARDS models.
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